Eupraxia to present at Jefferies Healthcare Conference
Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share that its management team will present at the Jefferies Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share that its management team will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 3, 2026, from 5:30PM to 6:00PM in New York, with 1x1 investor meetings on June 3 and 4.
Eupraxia is a clinical-stage biotechnology company developing locally delivered, extended-release treatments using its proprietary Diffusphere™ micro-sphere technology. Its pipeline includes EP-104GI in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis and EP-104IAR, which met the primary endpoint in a Phase 2b knee osteoarthritis pain trial.
Key Figures
Conference presentation date: June 3, 2026
Presentation time: 5:30PM–6:00PM
1x1 meeting dates: June 3–4, 2026
+2 more
5 metrics
Conference presentation date
June 3, 2026
Jefferies Global Healthcare Conference presentation
Presentation time
5:30PM–6:00PM
Jefferies Global Healthcare Conference session
1x1 meeting dates
June 3–4, 2026
Investor meetings during Jefferies conference
EP-104GI trial phase
Phase 1b/2
RESOLVE trial for eosinophilic esophagitis (EoE)
EP-104IAR trial phase
Phase 2b
SPRINGBOARD trial in knee osteoarthritis pain
Key Terms
Diffusphere™, clinical-stage biotechnology company, Phase 1b/2 trial, eosinophilic esophagitis, +2 more
6 terms
Diffusphere™ medical
"Diffusphere™ technology designed to optimize local, controlled drug delivery"
clinical-stage biotechnology company financial
"a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology"
Phase 1b/2 trial medical
"EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial"
eosinophilic esophagitis medical
"the RESOLVE trial, for the treatment of EoE"
A chronic allergic condition in which a type of white blood cell builds up in the tube that carries food from the mouth to the stomach, causing inflammation, difficulty swallowing and chest or throat pain; think of it as sticky residue narrowing a pipe. It matters to investors because prevalence, diagnostic rates and treatment options drive demand for drugs, tests and procedures, and clinical or regulatory news can quickly change revenue and valuation for healthcare companies working on therapies or diagnostics.
Phase 2b clinical trial medical
"Eupraxia also completed a Phase 2b clinical trial (SPRINGBOARD)"
A phase 2b clinical trial is a mid-stage medical study that tests whether a new treatment works and which dose is best by enrolling a larger group of patients than earlier phase 2 studies. For investors, its results are a key signal of a drug’s real-world effectiveness and safety, and can strongly influence the chances of later regulatory approval, future funding needs, and a company’s stock outlook—like a larger pilot test before full rollout.
knee osteoarthritis medical
"Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis"
A degenerative condition in which the cushioning tissue in the knee joint gradually wears away, causing pain, stiffness and reduced mobility. For investors it matters because it creates steady demand for medicines, medical devices, surgeries and rehabilitation services, influences healthcare costs and reimbursement decisions, and drives clinical trials and regulatory reviews—similar to how a worn-out shock absorber creates a predictable need for repairs or replacements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Eupraxia Pharmaceuticals (EPRX) announce in this Form 6-K?
Eupraxia Pharmaceuticals announced its management will present at the Jefferies Global Healthcare Conference on June 3, 2026, in New York. The company will also hold 1x1 investor meetings on June 3 and 4, highlighting its clinical-stage pipeline and Diffusphere™ drug delivery technology.
When and where is Eupraxia presenting at the Jefferies Global Healthcare Conference?
Eupraxia will present at the Jefferies Global Healthcare Conference on June 3, 2026, from 5:30PM to 6:00PM in New York. The company will also participate in 1x1 meetings with investors on June 3 and 4 during the same conference, offering more detailed discussions.
What is Eupraxia Pharmaceuticals’ core technology platform?
Eupraxia’s core platform is its proprietary Diffusphere™ polymer-based micro-sphere technology for local, controlled drug delivery. It is designed to provide extended duration of effect and hyper-localized treatment, aiming to improve safety, tolerability, efficacy, and duration for both existing and novel drugs across multiple therapeutic areas.
Which clinical programs did Eupraxia highlight in this disclosure?
Eupraxia highlighted EP-104GI, in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis, and EP-104IAR, which completed a Phase 2b SPRINGBOARD trial in knee osteoarthritis pain. The EP-104IAR trial met its primary endpoint and three of four secondary endpoints, supporting further development plans.
What diseases is Eupraxia Pharmaceuticals currently targeting with its pipeline?
Eupraxia is targeting pain and inflammatory gastrointestinal disease, including eosinophilic esophagitis and knee osteoarthritis, with its lead programs. The company also notes potential applications of its Diffusphere™ technology in other inflammatory joint indications, oncology, infectious disease, and additional critical disease areas under exploration.
How can investors access Eupraxia’s Jefferies conference presentation?
Investors can access Eupraxia’s Jefferies Global Healthcare Conference presentation via a webcast registration link provided in the announcement. Those interested in 1x1 meetings are instructed to contact their Jefferies representative to arrange sessions with the Eupraxia management team during the June 3–4, 2026 dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates